BIOMAT Database Logo BIOMAT Database Logo

Double-blind, crossover trial of fluoxetine and placebo in children and adolescents with obsessive-compulsive disorder. 1992

M A Riddle, and L Scahill, and R A King, and M T Hardin, and G M Anderson, and S I Ort, and J C Smith, and J F Leckman, and D J Cohen
Yale Child Study Center, Yale University School of Medicine, New Haven, CT 06510-8009.

Rigorously designed clinical trials have demonstrated the efficacy and safety of fluoxetine in adults with major depressive disorder and obsessive-compulsive disorder (OCD) but not in patients below 18 years old. This report describes a randomized, double-blind, placebo-controlled, fixed-dose (20 mg qd) trial of fluoxetine in 14 children and adolescents with OCD, ages 8 to 15 years old; the study was 20 weeks long with crossover at 8 weeks. Obsessive-compulsive symptom severity was measured on the Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS) and the Clinician's Global Impression-Obsessive Compulsive Disorder scale (CGI-OCD). The CY-BOCS total score decreased 44% (N = 7, p = .003) after the initial 8 weeks of fluoxetine treatment, compared with a 27% decrease (N = 6, p = .13) after placebo. During the initial 8 weeks, the magnitude of improvement for the fluoxetine group significantly exceeded that for the placebo group as measured by the CGI-OCD (p = .01) but not by the CY-BOCS (p = .17). The most common drug side effects were generally well tolerated. The results suggest that fluoxetine is a generally safe and effective short-term treatment for children with OCD.

UI MeSH Term Description Entries
D008297 Male Males
D009771 Obsessive-Compulsive Disorder An anxiety disorder characterized by recurrent, persistent obsessions or compulsions. Obsessions are the intrusive ideas, thoughts, or images that are experienced as senseless or repugnant. Compulsions are repetitive and seemingly purposeful behavior which the individual generally recognizes as senseless and from which the individual does not derive pleasure although it may provide a release from tension. Anankastic Personality,Neurosis, Obsessive-Compulsive,Anankastic Personalities,Disorder, Obsessive-Compulsive,Disorders, Obsessive-Compulsive,Neuroses, Obsessive-Compulsive,Neurosis, Obsessive Compulsive,Obsessive Compulsive Disorder,Obsessive-Compulsive Disorders,Obsessive-Compulsive Neuroses,Obsessive-Compulsive Neurosis,Personalities, Anankastic,Personality, Anankastic
D010552 Personality Assessment The determination and evaluation of personality attributes by interviews, observations, tests, or scales. Articles concerning personality measurement are considered to be within scope of this term. Assessment, Personality,Assessments, Personality,Personality Assessments
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D005260 Female Females
D005473 Fluoxetine The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants. Fluoxetin,Fluoxetine Hydrochloride,Lilly-110140,N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine,Prozac,Sarafem,Lilly 110140,Lilly110140
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths

Related Publications

M A Riddle, and L Scahill, and R A King, and M T Hardin, and G M Anderson, and S I Ort, and J C Smith, and J F Leckman, and D J Cohen
Tolcapone in obsessive-compulsive disorder: a randomized double-blind placebo-controlled crossover trial.
September 2021, International clinical psychopharmacology,
M A Riddle, and L Scahill, and R A King, and M T Hardin, and G M Anderson, and S I Ort, and J C Smith, and J F Leckman, and D J Cohen
A double-blind, placebo-controlled trial of olanzapine addition in fluoxetine-refractory obsessive-compulsive disorder.
March 2004, Biological psychiatry,
M A Riddle, and L Scahill, and R A King, and M T Hardin, and G M Anderson, and S I Ort, and J C Smith, and J F Leckman, and D J Cohen
Paroxetine treatment in children and adolescents with obsessive-compulsive disorder: a randomized, multicenter, double-blind, placebo-controlled trial.
November 2004, Journal of the American Academy of Child and Adolescent Psychiatry,
M A Riddle, and L Scahill, and R A King, and M T Hardin, and G M Anderson, and S I Ort, and J C Smith, and J F Leckman, and D J Cohen
Fluoxetine treatment for obsessive-compulsive disorder in children and adolescents: a placebo-controlled clinical trial.
July 2001, Journal of the American Academy of Child and Adolescent Psychiatry,
M A Riddle, and L Scahill, and R A King, and M T Hardin, and G M Anderson, and S I Ort, and J C Smith, and J F Leckman, and D J Cohen
Treatment of obsessive-compulsive disorder with clomipramine and desipramine in children and adolescents. A double-blind crossover comparison.
December 1989, Archives of general psychiatry,
M A Riddle, and L Scahill, and R A King, and M T Hardin, and G M Anderson, and S I Ort, and J C Smith, and J F Leckman, and D J Cohen
A double-blind, placebo-controlled trial of clonazepam in obsessive-compulsive disorder.
January 2003, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry,
M A Riddle, and L Scahill, and R A King, and M T Hardin, and G M Anderson, and S I Ort, and J C Smith, and J F Leckman, and D J Cohen
A double-blind, randomized, controlled trial of fluoxetine plus quetiapine or clomipramine versus fluoxetine plus placebo for obsessive-compulsive disorder.
December 2011, Journal of clinical psychopharmacology,
M A Riddle, and L Scahill, and R A King, and M T Hardin, and G M Anderson, and S I Ort, and J C Smith, and J F Leckman, and D J Cohen
Reboxetine Combination Therapy With Fluoxetine in Moderate to Severe Obsessive-Compulsive Disorder: A Placebo-Controlled, Double-Blind, Randomized Trial.
January 2023, Clinical neuropharmacology,
M A Riddle, and L Scahill, and R A King, and M T Hardin, and G M Anderson, and S I Ort, and J C Smith, and J F Leckman, and D J Cohen
Fluoxetine for adolescents with obsessive-compulsive disorder.
March 1990, The American journal of psychiatry,
M A Riddle, and L Scahill, and R A King, and M T Hardin, and G M Anderson, and S I Ort, and J C Smith, and J F Leckman, and D J Cohen
Placebo-controlled trial of fluoxetine and phenelzine for obsessive-compulsive disorder.
September 1997, The American journal of psychiatry,
Copied contents to your clipboard!